Randomized controlled expressive writing pilot in individuals with Parkinson's disease and their caregivers

Therese Verkerke Cash, Sarah K Lageman, Therese Verkerke Cash, Sarah K Lageman

Abstract

Background: Individuals with Parkinson's disease (PD) and their caregivers are at risk for emotional distress and hypercortisolism. Expressive writing is an effective complementary intervention to ameliorate the psychological and physiological effects of chronic illness. This pilot study aimed to evaluate feasibility and preliminary effectiveness of an expressive writing intervention for individuals with PD and their caregivers.

Methods: Individuals with PD (N = 27) and their caregivers (N = 14) were randomly assigned to expressive (N = 15 patients, eight caregivers) or neutral (N = 12 patients, six caregivers) writing conditions. Cortisol awakening response (CAR), non-motor functioning, quality of life, and performance on tests of cognitive functioning were assessed at baseline, immediate post, 4-month, and 10-month post intervention.

Results: Attrition was a challenge as eight patients (29.62 %) and four caregivers (28.57 %) chose to discontinue before beginning the intervention or were lost to follow up prior to completing the intervention or the first follow up visit. Significant reduction in anxiety, marginally significant improvement in depression and caregiver burden, and significant improvements in performance on tests of learning and memory were observed, but these changes did not differ by writing condition. CAR significantly differed over time between patients and caregivers and writing conditions.

Conclusions: Some evidence for the feasibility and effectiveness of writing to alleviate hypercortisolism was demonstrated in a small sample of PD patients; however, relatively high attrition rates and the lack of difference between expressive and neutral writing conditions on emotional and neurocognitive outcomes suggests expressive writing procedure modifications may be needed to obtain optimal results for this population.

Trial registration: ClinicalTrials.gov, NCT02217735 , Study Start Date: August 30, 2011.

References

    1. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36–42. doi: 10.1136/jnnp.2005.083113.
    1. Baikie KA, Wilhelm K. Emotional and physical health benefits of expressive writing. Adv Psychiatr Treat. 2005;11:338–346. doi: 10.1192/apt.11.5.338.
    1. Beck A. Depression causes and treatment. Philadelphia: University of Pennsylvania Press; 1967.
    1. Bédard M, Molloy DW, Squire L, Dubois S, Lever JA, O’Donnell M. The zarit burden interview: a new short version and screening version. The Gerontologist. 2001;41(5):652–657. doi: 10.1093/geront/41.5.652.
    1. Broderick JE, Junghaenel DU, Schwartz JE. Written emotional expression produces health benefits in fibromyalgia patients. Psychosom Med. 2005;67(2):326–334. doi: 10.1097/.
    1. Brown J. Some tests of the decay of immediate memory. Q J Exp Psychol. 1958;10:12–21. doi: 10.1080/17470215808416249.
    1. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–923. doi: 10.1002/mds.20844.
    1. Chida Y, Steptoe A. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. Biol Psychol. 2009;80(3):265–278. doi: 10.1016/j.biopsycho.2008.10.004.
    1. de Moor C, Sterner J, Hall M, Warneke C, Gilani Z, Amato R, et al. A pilot study of the effects of expressive writing on psychological and behavioral adjustment in patients enrolled in a phase II trial of vaccine therapy for metastatic renal cell carcinoma. Health Psychol. 2002;21(6):615–619. doi: 10.1037/0278-6133.21.6.615.
    1. de Vugt ME, Nicolson NA, Aalten P, Lousberg R, Jolle J, Verhey FR. Behavioral problems in dementia patients and salivary cortisol patterns in caregivers. J Neuropsychiatry Clin Neurosci. 2005;17(2):201–207. doi: 10.1176/jnp.17.2.201.
    1. Delis DC, Kramer JH, Kaplan E, Ober BA. California verbal learning test- adult version. 2. San Antonio: Pearson; 2000.
    1. Djamshidian A, O’Sullivan SS, Papadopoulos A, Bassett P, Shaw K, Averbeck BB, et al. Salivary cortisol levels in parkinson’s disease and its correlation to risk behaviour. J Neurol Neurosurg Psychiatry. 2011;82(10):1107–1111. doi: 10.1136/jnnp.2011.245746.
    1. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitive-behavioral therapy for depression in parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–1074. doi: 10.1176/appi.ajp.2011.10111669.
    1. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The Measurement of Everyday Cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22:531–544. doi: 10.1037/0894-4105.22.4.531.
    1. Fonteyn ME, Vettese M, Lancaster DR, Bauer-Wu S. Developing a codebook to guide content analysis of expressive writing transcripts. Appl Nurs Res. 2008;21(3):165–168. doi: 10.1016/j.apnr.2006.08.005.
    1. Frattaroli J. Experimental disclosure and its moderators: a meta-analysis. Psychol Bull. 2006;132(6):823–865. doi: 10.1037/0033-2909.132.6.823.
    1. Gallagher D, Nies G, Thompson LW. Reliability of the beck depression inventory with older adults. J Consult Clin Psychol. 1982;50(1):152–153. doi: 10.1037/0022-006X.50.1.152.
    1. George D, Mallery P. SPSS for Windows step by step: a simple guide and reference. 11.0 update. 4. Boston: Allyn & Bacon; 2003.
    1. Graham JE, Lobel M, Glass P, Lokshina I. Effects of written anger expression in chronic pain patients: making meaning from pain. J Behav Med. 2008;31(3):201–212. doi: 10.1007/s10865-008-9149-4.
    1. Greenaway MC, Duncan NL, Smith GE. The memory support system for mild cognitive impairment: randomized trial of a cognitive rehabilitation intervention. Int J Geriatr Psychiatry. 2013;28(4):402–409. doi: 10.1002/gps.3838.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with alzheimer’s and parkinson’s disease compared to normal controls: Ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18(3):285–289. doi: 10.1016/S0197-4580(97)80309-0.
    1. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded halstead-reitan battery: demographically adjusted neuropsychological norms for african american and caucasian adults: professional manual. Lutz: Psychological Assessment Resources, Inc.; 2004.
    1. Hellhammer J, Fries E, Schweisthal OW, Schlotz W, Stone AA, Hagemann D. Several daily measurements are necessary to reliably assess the cortisol rise after awakening: State- and trait components. Psychoneuroendocrinology. 2007;32(1):80–86. doi: 10.1016/j.psyneuen.2006.10.005.
    1. Herrera C, Chambon C, Michel BF, Paban V, Alescio-Lautier B. Positive effects of computer-based cognitive training in adults with mild cognitive impairment. Neuropsychologia. 2012;50(8):1871–1881. doi: 10.1016/j.neuropsychologia.2012.04.012.
    1. Ivnik RJ, Smith GE, Lucas JA, Petersen RC, Boeve BF, Kokmen E, et al. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. Neuropsychology. 1999;13(1):121–127. doi: 10.1037/0894-4105.13.1.121.
    1. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The parkinson’s disease questionnaire (PDQ-39): development and validation of a parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–357. doi: 10.1093/ageing/26.5.353.
    1. Klein K, Boals A. Expressive writing can increase working memory capacity. J Exp Psychol Gen. 2001;130(3):520–533. doi: 10.1037/0096-3445.130.3.520.
    1. Lageman S, Cash T, Mickens M. A-50: feasibility and initial results of a randomized-controlled computer-based cognitive training trial in individuals with parkinson’s disease. Arch Clin Neuropsychol. 2014;29(6):521–522. doi: 10.1093/arclin/acu038.50.
    1. Lageman S, Cash T, Mickens M. A-51: preliminary outcome data of a clinical trial comparing a neurocognitive intervention to supportive therapy in individuals with parkinson’s disease. Arch Clin Neuropsychol. 2014;29(6):522. doi: 10.1093/arclin/acu038.51.
    1. Lageman SK, Cash TV, Mickens MN. Patient-reported needs, non-motor symptoms, and quality of life in essential tremor and parkinson’s disease. Tremor Other Hyperkinet Mov. 2014;4:240.
    1. Locke DE, Decker PA, Sloan JA, Brown PD, Malec JF, Clark MM, et al. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manag. 2007;34(6):628–638. doi: 10.1016/j.jpainsymman.2007.01.016.
    1. Mackenzie CS, Wiprzycka UJ, Hasher L, Goldstein D. Does expressive writing reduce stress and improve health for family caregivers of older adults? The Gerontologist. 2007;47(3):296–306. doi: 10.1093/geront/47.3.296.
    1. Manier D, Olivares A. Who benefits from expressive writing? Moderator variables affecting outcomes of emotional disclosure interventions. Couns Clin Psychol J. 2005;2:15–28.
    1. McGuire KM, Greenberg MA, Gevirtz R. Autonomic effects of expressive writing in individuals with elevated blood pressure. J Health Psychol. 2005;10(2):197–209. doi: 10.1177/1359105305049767.
    1. Mogk C, Otte S, Reinhold-Hurley B, Kroner-Herwig B. Health effects of expressive writing on stressful or traumatic experiences - a meta-analysis. GMS Psycho-Soc Med. 2006;3:Doc06.
    1. Pennebaker JW, Beall SK. Confronting a traumatic event: toward an understanding of inhibition and disease. J Abnorm Psychol. 1986;95(3):274–281. doi: 10.1037/0021-843X.95.3.274.
    1. Peterson LR, Peterson MJ. Short-term retention of individual verbal items. J Exp Psychol. 1959;58:193–198. doi: 10.1037/h0049234.
    1. Pruessner JC, Wolf OT, Hellhammer DH, Buske-Kirschbaum A, von Auer K, Jobst S, et al. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997;61(26):2539–2549. doi: 10.1016/S0024-3205(97)01008-4.
    1. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–276. doi: 10.2466/pms.1958.8.3.271.
    1. Reynolds W. Multidimensional anxiety questionnaire: Professional Manual. Odessa: Psychological Assessment Resources, Inc.; 1999.
    1. Rosenberg HJ, Rosenberg SD, Ernstoff MS, Wolford GL, Amdur RJ, Elshamy MR, et al. Expressive disclosure and health outcomes in a prostate cancer population. Int J Psychiatry Med. 2002;32(1):37–53. doi: 10.2190/AGPF-VB1G-U82E-AE8C.
    1. Schwartz L, Drotar D. Effects of written emotional disclosure on caregivers of children and adolescents with chronic illness. J Pediatr Psychol. 2004;29(2):105–118. doi: 10.1093/jpepsy/jsh014.
    1. Secker DL, Brown RG. Cognitive behavioural therapy (CBT) for carers of patients with parkinson’s disease: a preliminary randomised controlled trial. J Neurol Neurosurg Psychiatry. 2005;76(4):491–497. doi: 10.1136/jnnp.2004.042291.
    1. Sloan DM, Marx BP. A closer examination of the structured written disclosure procedure. J Consult Clin Psychol. 2004;72:165–175. doi: 10.1037/0022-006X.72.2.165.
    1. Smyth JM. Written emotional expression: effect sizes, outcome types, and moderating variables. J Consult Clin Psychol. 1998;66(1):174–184. doi: 10.1037/0022-006X.66.1.174.
    1. Smyth JM. Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomized trial. JAMA. 1999;281:1304–1309. doi: 10.1001/jama.281.14.1304.
    1. Smyth JM, Hockemeyer JR, Tulloch H. Expressive writing and post-traumatic stress disorder: effects on trauma symptoms, mood states, and cortisol reactivity. Br J Health Psychol. 2008;13(Pt 1):85–93. doi: 10.1348/135910707X250866.
    1. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139. doi: 10.1176/jnp.4.2.134.
    1. Törnhage CJ, Skogar O, Borg A, Larsson B, Robertsson L, Andersson L, et al. Short- and long-term effects of tactile massage on salivary cortisol concentrations in parkinson’s disease: a randomised controlled pilot study. BMC Complement Altern Med. 2013;13:357. doi: 10.1186/1472-6882-13-357.
    1. Tröster AI, Fields JA. Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration, and related disorders of the frontostriatal system. In: Morgan JE, Ricker JH, editors. Textbook of clinical neuropsychology. New York: Taylor & Francis; 2008. pp. 536–577.
    1. Wahbeh H, Kishiyama SS, Zajdel D, Oken BS. Salivary cortisol awakening response in mild alzheimer disease, caregivers, and noncaregivers. Alzheimer Dis Assoc Disord. 2008;22(2):181–183. doi: 10.1097/WAD.0b013e31815a9dff.
    1. Wechsler D. Wechsler adult intelligence scale (WAIS-IV): technical and interpretive manual. 4. San Antonio: Pearson; 2008.
    1. Zakowski SG, Ramati A, Morton C, Johnson P, Flanigan R. Written emotional disclosure buffers the effects of social constraints on distress among cancer patients. Health Psychol. 2004;23(6):555–563. doi: 10.1037/0278-6133.23.6.555.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel